Session Type
Date Time
Local Date Time

The Dual Prevention Pill (DPP), a co-formulated tablet containing oral pre-exposure prophylaxis (PrEP) and a combined oral contraceptive, is likely to be the first MPT with PrEP to go to market. By combining contraception and PrEP, the DPP could address women's concurrent needs for a method that prevents both pregnancy and HIV and mitigates the challenges of stigma and partner dynamics that women face taking PrEP alone. Coordinated introduction efforts could bridge persistent silos in financing and health systems; respond to users' desires; galvanize providers, who will be key players in DPP provision; and expedite the introduction of other MPTs. Using the DPP as a case study, this session will highlight practical considerations for future MPTs and aim to answer questions such as: What are entry points and best practices with end users and providers? How do different financing streams for family planning and HIV influence product delivery opportunities? What approaches can be used to estimate impact? Presenters will share their work on the DPP to inform the MPT landscape.

10 min
Introduction: Why the DPP is a case study for future MPTs
Jessica RODRIGUES, AVAC, United States
10 min
What users want: Potential entry points and barriers for women
Natasha SALIFYANJI KAOMA, Copper Rose Zambia, Zambia
10 min
Client and provider perspectives: Emerging findings from formative research in South Africa and Zimbabwe
Adlight DANDADZI, University of Zimbabwe-Clinical Trials Research Centre, Zimbabwe
Siyanda TENZA, Wits Reproductive Health and HIV Institute (Wits RHI), South Africa
10 min
Planning for investment: Considerations for modeling impact and cost-effectiveness for an MPT
Danielle RESAR, Clinton Health Access Initiative, United States
45 min
Panel: Bridging HIV and FP silos: Stakeholder perspectives on opportunities and obstacles for the DPP and MPTs
Jessica RODRIGUES, AVAC, United States
Taryn BARKER, CIFF, United Kingdom
Chris JONES, Mann Global Health, United States
Kellen THOMAS, Viatris, United States
Loyiso SALISO, Advocates for the Prevention of HIV in Africa (APHA), South Africa
Hasina SUBEDAR, National Department of Health, South Africa
Mande LIMBU, FP2030, United States
5 min
Closing: Key takeaways for the DPP and implications for future MPTs
Taryn BARKER, CIFF, United Kingdom